Novo Nordisk

News

Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.

News

Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.

News

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide.

News

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.

News

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.